- Record: found
- Abstract: found
- Article: not found
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Brian I Rini
1 ,
Susan Halabi ,
Jonathan E Rosenberg ,
Walter M Stadler ,
Daniel A Vaena ,
Laura Archer ,
James N Atkins ,
Joel Picus ,
Piotr Czaykowski ,
Janice Dutcher ,
Eric J Small
May 01 2010
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-alpha versus IFN-alpha monotherapy was conducted.